Effect of BAY u3405, a thromboxane A2 receptor antagonist, on neuro-effector transmission in canine tracheal tissue

H. Aizawa, S. Takata, M. Shigyo, Koichiro Matsumoto, H. Koto, H. Inoue, N. Hara

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Thromboxane A2 (TXA2) is reported to potentiate vagal nerve neuro-effector transmission in airway smooth muscle tissue. We investigated the effects of BAY u3405 (3(R)-[[4-fluorophenyl)sulfonyl]amino]-1,2,3,4,-tetrahydro-9H-carbazole- 9-propanoic acid), a potent and selective TXA2 receptor antagonist, on the increase in vagal nerve neuro-effector transmission induced by a TXA2 mimetic, U-46619, in the canine trachea. We measured the contractions of canine tracheal smooth muscle evoked by electrical field stimulation (EFS) and by acetylcholine (ACh) in the presence and absence of a subthreshold dose of U-46619 (the highest dose that did not induce any smooth muscle contraction). We then examined whether BAY u3405 inhibited the effect of U-46619 on tracheal smooth muscle. The following results were obtained: (i) subthreshold doses of U-46619 (10-10 M and 10-9 M) significantly increased the amplitude of the contractions evoked by EFS; (ii) by contrast, U-46619 had no effect on the contractile response of smooth muscle to exogenously applied ACh; (iii) the contraction evoked by EFS was completely abolished by the application of atropine (10-6 M) or tetrodotoxin (10-7 M), indicating that EFS caused the smooth muscle contraction through the release of ACh from vagal nerve terminals; and (iv) pretreatment with BAY u3405 (10-6 M) abolished the excitatory action of U-46619 on the amplitude of twitch contraction evoked by EFS in the trachea. These results indicate that U-46619, at low concentrations, has a prejunctional action stimulating neuro-effector transmission, presumably increasing ACh release from vagal nerve terminals through TXA2 receptors. The inhibitory action of BAY u3405 on the TXA2-induced enhancement of vagal nerve neuro-effector transmission may be useful in the treatment of bronchial asthma.

Original languageEnglish
Pages (from-to)213-217
Number of pages5
JournalProstaglandins, Leukotrienes and Essential Fatty Acids
Volume53
Issue number3
DOIs
Publication statusPublished - Jan 1 1995

Fingerprint

Prostaglandin H2 Receptors Thromboxane A2
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
Canidae
Smooth Muscle
Muscle
Tissue
Electric Stimulation
Thromboxane A2
Acetylcholine
Muscle Contraction
Trachea
Tetrodotoxin
ramatroban
Atropine
Asthma
Muscles

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry
  • Cell Biology

Cite this

Effect of BAY u3405, a thromboxane A2 receptor antagonist, on neuro-effector transmission in canine tracheal tissue. / Aizawa, H.; Takata, S.; Shigyo, M.; Matsumoto, Koichiro; Koto, H.; Inoue, H.; Hara, N.

In: Prostaglandins, Leukotrienes and Essential Fatty Acids, Vol. 53, No. 3, 01.01.1995, p. 213-217.

Research output: Contribution to journalArticle

@article{4e0c799a8be145d08b318d30e5de415b,
title = "Effect of BAY u3405, a thromboxane A2 receptor antagonist, on neuro-effector transmission in canine tracheal tissue",
abstract = "Thromboxane A2 (TXA2) is reported to potentiate vagal nerve neuro-effector transmission in airway smooth muscle tissue. We investigated the effects of BAY u3405 (3(R)-[[4-fluorophenyl)sulfonyl]amino]-1,2,3,4,-tetrahydro-9H-carbazole- 9-propanoic acid), a potent and selective TXA2 receptor antagonist, on the increase in vagal nerve neuro-effector transmission induced by a TXA2 mimetic, U-46619, in the canine trachea. We measured the contractions of canine tracheal smooth muscle evoked by electrical field stimulation (EFS) and by acetylcholine (ACh) in the presence and absence of a subthreshold dose of U-46619 (the highest dose that did not induce any smooth muscle contraction). We then examined whether BAY u3405 inhibited the effect of U-46619 on tracheal smooth muscle. The following results were obtained: (i) subthreshold doses of U-46619 (10-10 M and 10-9 M) significantly increased the amplitude of the contractions evoked by EFS; (ii) by contrast, U-46619 had no effect on the contractile response of smooth muscle to exogenously applied ACh; (iii) the contraction evoked by EFS was completely abolished by the application of atropine (10-6 M) or tetrodotoxin (10-7 M), indicating that EFS caused the smooth muscle contraction through the release of ACh from vagal nerve terminals; and (iv) pretreatment with BAY u3405 (10-6 M) abolished the excitatory action of U-46619 on the amplitude of twitch contraction evoked by EFS in the trachea. These results indicate that U-46619, at low concentrations, has a prejunctional action stimulating neuro-effector transmission, presumably increasing ACh release from vagal nerve terminals through TXA2 receptors. The inhibitory action of BAY u3405 on the TXA2-induced enhancement of vagal nerve neuro-effector transmission may be useful in the treatment of bronchial asthma.",
author = "H. Aizawa and S. Takata and M. Shigyo and Koichiro Matsumoto and H. Koto and H. Inoue and N. Hara",
year = "1995",
month = "1",
day = "1",
doi = "10.1016/0952-3278(95)90119-1",
language = "English",
volume = "53",
pages = "213--217",
journal = "Prostaglandins Leukotrienes and Essential Fatty Acids",
issn = "0952-3278",
publisher = "Churchill Livingstone",
number = "3",

}

TY - JOUR

T1 - Effect of BAY u3405, a thromboxane A2 receptor antagonist, on neuro-effector transmission in canine tracheal tissue

AU - Aizawa, H.

AU - Takata, S.

AU - Shigyo, M.

AU - Matsumoto, Koichiro

AU - Koto, H.

AU - Inoue, H.

AU - Hara, N.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Thromboxane A2 (TXA2) is reported to potentiate vagal nerve neuro-effector transmission in airway smooth muscle tissue. We investigated the effects of BAY u3405 (3(R)-[[4-fluorophenyl)sulfonyl]amino]-1,2,3,4,-tetrahydro-9H-carbazole- 9-propanoic acid), a potent and selective TXA2 receptor antagonist, on the increase in vagal nerve neuro-effector transmission induced by a TXA2 mimetic, U-46619, in the canine trachea. We measured the contractions of canine tracheal smooth muscle evoked by electrical field stimulation (EFS) and by acetylcholine (ACh) in the presence and absence of a subthreshold dose of U-46619 (the highest dose that did not induce any smooth muscle contraction). We then examined whether BAY u3405 inhibited the effect of U-46619 on tracheal smooth muscle. The following results were obtained: (i) subthreshold doses of U-46619 (10-10 M and 10-9 M) significantly increased the amplitude of the contractions evoked by EFS; (ii) by contrast, U-46619 had no effect on the contractile response of smooth muscle to exogenously applied ACh; (iii) the contraction evoked by EFS was completely abolished by the application of atropine (10-6 M) or tetrodotoxin (10-7 M), indicating that EFS caused the smooth muscle contraction through the release of ACh from vagal nerve terminals; and (iv) pretreatment with BAY u3405 (10-6 M) abolished the excitatory action of U-46619 on the amplitude of twitch contraction evoked by EFS in the trachea. These results indicate that U-46619, at low concentrations, has a prejunctional action stimulating neuro-effector transmission, presumably increasing ACh release from vagal nerve terminals through TXA2 receptors. The inhibitory action of BAY u3405 on the TXA2-induced enhancement of vagal nerve neuro-effector transmission may be useful in the treatment of bronchial asthma.

AB - Thromboxane A2 (TXA2) is reported to potentiate vagal nerve neuro-effector transmission in airway smooth muscle tissue. We investigated the effects of BAY u3405 (3(R)-[[4-fluorophenyl)sulfonyl]amino]-1,2,3,4,-tetrahydro-9H-carbazole- 9-propanoic acid), a potent and selective TXA2 receptor antagonist, on the increase in vagal nerve neuro-effector transmission induced by a TXA2 mimetic, U-46619, in the canine trachea. We measured the contractions of canine tracheal smooth muscle evoked by electrical field stimulation (EFS) and by acetylcholine (ACh) in the presence and absence of a subthreshold dose of U-46619 (the highest dose that did not induce any smooth muscle contraction). We then examined whether BAY u3405 inhibited the effect of U-46619 on tracheal smooth muscle. The following results were obtained: (i) subthreshold doses of U-46619 (10-10 M and 10-9 M) significantly increased the amplitude of the contractions evoked by EFS; (ii) by contrast, U-46619 had no effect on the contractile response of smooth muscle to exogenously applied ACh; (iii) the contraction evoked by EFS was completely abolished by the application of atropine (10-6 M) or tetrodotoxin (10-7 M), indicating that EFS caused the smooth muscle contraction through the release of ACh from vagal nerve terminals; and (iv) pretreatment with BAY u3405 (10-6 M) abolished the excitatory action of U-46619 on the amplitude of twitch contraction evoked by EFS in the trachea. These results indicate that U-46619, at low concentrations, has a prejunctional action stimulating neuro-effector transmission, presumably increasing ACh release from vagal nerve terminals through TXA2 receptors. The inhibitory action of BAY u3405 on the TXA2-induced enhancement of vagal nerve neuro-effector transmission may be useful in the treatment of bronchial asthma.

UR - http://www.scopus.com/inward/record.url?scp=0029118669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029118669&partnerID=8YFLogxK

U2 - 10.1016/0952-3278(95)90119-1

DO - 10.1016/0952-3278(95)90119-1

M3 - Article

C2 - 7480085

AN - SCOPUS:0029118669

VL - 53

SP - 213

EP - 217

JO - Prostaglandins Leukotrienes and Essential Fatty Acids

JF - Prostaglandins Leukotrienes and Essential Fatty Acids

SN - 0952-3278

IS - 3

ER -